Cytek Biosciences (CTKB) Current Assets (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Current Assets data on file, last reported at $379.3 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets changed 0.32% year-over-year to $379.3 million; the trailing twelve-month figure through Mar 2026 stood at $379.3 million (changed 0.32% YoY), and the FY2025 full-year result was $392.0 million, down 1.12% from the prior year.
• Current Assets for Q1 2026 stood at $379.3 million, down from $392.0 million in the prior quarter.
• Across five years, Current Assets topped out at $454.0 million in Q4 2022 and bottomed at $379.3 million in Q1 2026.
• The 5-year median for Current Assets is $392.1 million (2023), against an average of $407.5 million.
• The widest annual swing landed in 2022, when Current Assets jumped 104.33%; it then declined 13.65% in 2023.
• A 5-year view of Current Assets shows it stood at $454.0 million in 2022, then decreased by 13.65% to $392.1 million in 2023, then gained by 1.12% to $396.4 million in 2024, then slipped by 1.12% to $392.0 million in 2025, then declined by 3.24% to $379.3 million in 2026.
• The last three Current Assets figures came in at $379.3 million (Q1 2026), $392.0 million (Q4 2025), and $388.5 million (Q3 2025), per Business Quant data.

Peer Comparison